Compare Dishman Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 25.1 94.0 26.7% View Chart
P/BV x 3.3 26.5 12.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-18
DISHMAN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,278 29.3%   
Low Rs129883 14.6%   
Sales per share (Unadj.) Rs197.8228.4 86.6%  
Earnings per share (Unadj.) Rs21.210.4 204.6%  
Cash flow per share (Unadj.) Rs34.716.3 213.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.998.8 182.1%  
Shares outstanding (eoy) m80.6925.00 322.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.7 26.9%   
Avg P/E ratio x11.9104.2 11.4%  
P/CF ratio (eoy) x7.266.4 10.9%  
Price / Book Value ratio x1.410.9 12.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30627,008 75.2%   
No. of employees `0000.81.4 61.1%   
Total wages/salary Rs m5,3551,535 348.8%   
Avg. sales/employee Rs Th19,252.74,210.9 457.2%   
Avg. wages/employee Rs Th6,459.51,132.2 570.5%   
Avg. net profit/employee Rs Th2,064.1191.1 1,080.2%   
INCOME DATA
Net Sales Rs m15,9615,710 279.5%  
Other income Rs m265123 216.7%   
Total revenues Rs m16,2265,833 278.2%   
Gross profit Rs m4,103463 886.4%  
Depreciation Rs m1,091147 739.9%   
Interest Rs m9440-   
Profit before tax Rs m2,334438 532.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624179 348.6%   
Profit after tax Rs m1,711259 660.4%  
Gross profit margin %25.78.1 317.1%  
Effective tax rate %26.740.8 65.4%   
Net profit margin %10.74.5 236.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,209 343.3%   
Current liabilities Rs m9,5172,070 459.9%   
Net working cap to sales %9.420.0 47.1%  
Current ratio x1.21.6 74.7%  
Inventory Days Days11072 152.7%  
Debtors Days Days3535 99.8%  
Net fixed assets Rs m16,304790 2,063.0%   
Share capital Rs m16150 322.8%   
"Free" reserves Rs m12,9072,419 533.5%   
Net worth Rs m14,5162,469 587.8%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8054,605 647.2%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 43.2%   
Return on assets %8.95.6 158.4%  
Return on equity %11.810.5 112.3%  
Return on capital %17.517.7 98.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952300 1,653.0%   
Fx outflow Rs m6972,015 34.6%   
Net fx Rs m4,255-1,715 -248.0%   
CASH FLOW
From Operations Rs m2,78688 3,170.0%  
From Investments Rs m-1,529-94 1,633.4%  
From Financial Activity Rs m-941NA-  
Net Cashflow Rs m316-6 -5,550.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 15.7 80.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 12,856 359.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC PHARMA  BIOCON   ELDER PHARMA  PFIZER  NATCO PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Telecom and Energy Stocks Gain the Most(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.4% while the Hang Seng is down 0.7%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS